Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res. 2016;5:26-38.
Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883-895.
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical practice guideline. J Clin Oncol. 2018;36:1714-1768.
Chung HC, Lopez-Martin JA, Kao CH, et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. J Clin Oncol. 2018;36: Abstract 8506.
Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): results from the KEYNOTE-028 and KEYNOTE-158 studies. Cancer Res. 2019;72(13_suppl): Abstract CT073.
ClinicalTrials.gov. Chemoradiation with or without atezolizumab in treating patients with limited stage small cell lung cancer. https://clinicaltrials.gov/ct2/show/NCT03811002. Accessed October 8, 2019.
DiBonaventura MD, Shah-Manek B, Higginbottom K, et al. Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan. Ther Clin Risk Manag. 2019;15:355-366.
Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018;7:69-79.
Goldman JW, Dowlati A, Antonia SJ, et al. Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC). J Clin Oncol. 2018;36(suppl): Abstract 8518.
Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-2229.
Liu S, Mansfield M, Szczesna A, et al. IMpower 133: Primary PFS, OS and safety in a PH1/3 Study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC. J Thorac Oncol. 2018;13: Abstract PL02.07.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: small cell lung cancer, version 2.2018. https://www2.tri-kobe.org/nccn/guideline/lung/english/small.pdf. Published January 17, 2018. Accessed October 8, 2019.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: small cell lung cancer, version 2.2019. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed October 15, 2019.
Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol. 2017;35:3823-3829.
Owonikoko TK, Kim HR, Govindan R, et al. Nivolumab plus ipilimumab, nivolumab, or placebo as maintenance therapy in patients with extensive disease small cell lung cancer after first line platinum based chemotherapy: results from the double blind, randomized phase 3 CheckMate 451 study. Ann Oncol. 2019;30: Abstract LBA1.
Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019. doi:10.1016/S0140-6736(19)32222-6. [Epub ahead of print]
Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 2012;131:1210-1219.
Ready N, Farago AF, de Braud F, et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019;14:237-240.
Reck M, Vicente D, Ciuleanu T, et al. Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from CheckMate 331. Ann Oncol. 2018;29: Abstract LBA5.
Senan S, Shire N, Mak G, et al. ADRIATIC: a phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer. Ann Oncol. 2019;30(Supplement_2): Abstract 67TiP.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Mark A. Socinski, MD

Executive Medical Director
Florida Hospital Cancer Institute
Orlando, Florida, United States

Disclosures

Disclosure: Mark A. Socinski, MD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Genentech, Inc.; Guardant; Novartis Pharmaceuticals Corporation; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Genentech, Inc.; Novartis Pharmaceuticals Corporation; Spectrum

Panelist

Hossein Borghaei, DO

Associate Professor
Department of Hematology and Oncology
Chief
Thoracic Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States

Disclosures

Disclosure: Hossein Borghaei, DO, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Axiom; BioNTech; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Cantargia AB; Celgene Corporation; EMD Serono, Inc.; Genentech, Inc.; GenMab; Huya Bio; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pharmamar; Regeneron Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Bristol-Myers Squibb Company; Celgene Corporation; Lilly; Merck & Co., Inc.; Millennium
Other: Data and safety monitoring board: Takeda Pharmaceuticals North America, Inc.

Riyaz Shah, MD

Consultant Medical Oncologist
Maidstone and Tunbridge Wells NHS Trust
Kent, United Kingdom

Disclosures

Disclosure: Riyaz Shah, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Merck Sharp & Dohme, Corp.; Pfizer Inc.; Roche; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Merck Sharp & Dohme, Corp.; Pfizer Inc.; Roche; Takeda Pharmaceuticals North America, Inc.

Editors

Elaine Hamarstrom, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Elaine Hamarstrom, PhD, has disclosed no relevant financial relationships.

Zachary Hartman, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Zachary Hartman, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Hazel Dennison, DNP, RN, FNP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Shining a Spotlight on Immunotherapy for Small Cell Lung Cancer

Authors: Mark Socinski, MD; Hossein Borghaei, DO; Riyaz Shah, MD
CME / ABIM MOC Released: 11/1/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/1/2020

Start Activity

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.

The goal of this activity is to provide insight on the evolving role of immune checkpoint inhibitors (ICIs) for the treatment of small cell lung cancer (SCLC).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical evidence supporting the use of ICI-based regimens for the treatment of extensive-stage (ES)-SCLC
- Rationale and design of clinical trials of ICI-based therapy in limited-stage (LS)-SCLC
Have greater competence related to
- Identifying appropriate patients with SCLC for ICI-based therapy

Disclosures

Moderator

Mark A. Socinski, MD

Executive Medical Director
Florida Hospital Cancer Institute
Orlando, Florida, United States

Disclosures

Disclosure: Mark A. Socinski, MD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Genentech, Inc.; Guardant; Novartis Pharmaceuticals Corporation; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Genentech, Inc.; Novartis Pharmaceuticals Corporation; Spectrum

Panelist

Hossein Borghaei, DO

Associate Professor
Department of Hematology and Oncology
Chief
Thoracic Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States

Disclosures

Disclosure: Hossein Borghaei, DO, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Axiom; BioNTech; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Cantargia AB; Celgene Corporation; EMD Serono, Inc.; Genentech, Inc.; GenMab; Huya Bio; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pharmamar; Regeneron Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Bristol-Myers Squibb Company; Celgene Corporation; Lilly; Merck & Co., Inc.; Millennium
Other: Data and safety monitoring board: Takeda Pharmaceuticals North America, Inc.

Riyaz Shah, MD

Consultant Medical Oncologist
Maidstone and Tunbridge Wells NHS Trust
Kent, United Kingdom

Disclosures

Disclosure: Riyaz Shah, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Merck Sharp & Dohme, Corp.; Pfizer Inc.; Roche; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Merck Sharp & Dohme, Corp.; Pfizer Inc.; Roche; Takeda Pharmaceuticals North America, Inc.

Editors

Elaine Hamarstrom, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Elaine Hamarstrom, PhD, has disclosed no relevant financial relationships.

Zachary Hartman, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Zachary Hartman, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Hazel Dennison, DNP, RN, FNP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Shining a Spotlight on Immunotherapy for Small Cell Lung Cancer

Authors: Mark Socinski, MD; Hossein Borghaei, DO; Riyaz Shah, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 11/1/2019

Valid for credit through: 11/1/2020

processing....

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Moderator

Mark A. Socinski, MD

Panelist

Hossein Borghaei, DO

Riyaz Shah, MD

Editors

Elaine Hamarstrom, PhD

Zachary Hartman, PhD

CME Reviewer

Hazel Dennison, DNP, RN, FNP

CME / ABIM MOC

Shining a Spotlight on Immunotherapy for Small Cell Lung Cancer

Target Audience and Goal Statement

Disclosures

Moderator

Mark A. Socinski, MD

Panelist

Hossein Borghaei, DO

Riyaz Shah, MD

Editors

Elaine Hamarstrom, PhD

Zachary Hartman, PhD

CME Reviewer

Hazel Dennison, DNP, RN, FNP

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Shining a Spotlight on Immunotherapy for Small Cell Lung Cancer

Educational Impact Challenge